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Edited by Jesus AvilaAbstract Brain glucose uptake/metabolism is impaired in
Alzheimer disease (AD). Here, we report that levels of the two
major brain glucose transporters (GLUT1 and GLUT3) respon-
sible for glucose uptake into neurons were decreased in AD
brain. This decrease correlated to the decrease in O-GlcNAcyla-
tion, to the hyperphosphorylation of tau, and to the density of
neuroﬁbrillary tangles in human brains. We also found down-
regulation of hypoxia-inducible factor 1, a major regulator of
GLUT1 and GLUT3, in AD brain. These studies provide a pos-
sible mechanism by which GLUT1 and GLUT3 deﬁciency could
cause impaired brain glucose uptake/metabolism and contribute
to neurodegeneration via down-regulation of O-GlcNAcylation
and hyperphosphorylation of tau in AD.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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factor1. Introduction
Alzheimer disease (AD) is characterized histopathologically
by extracellular amyloid plaques and intracellular neuroﬁbril-
lary tangles (NFTs). The number of tangles in the brain corre-
lates to dementia symptoms [1–3], suggesting that
neuroﬁbrillary degeneration may contribute to the pathogene-
sis of AD. NFTs are mainly composed of abnormally hyper-
phosphorylated tau that aggregates into paired helical
ﬁlaments and straight ﬁlaments [4]. Many studies have demon-
strated that abnormal hyperphosphorylation of tau is crucial
to neurodegeneration [5,6]. Although extensive studies have
been carried out on protein kinases and phosphatases that reg-
ulate tau phosphorylation, the mechanisms leading to the
abnormal hyperphosphorylation of tau in AD brain are not
well understood.
Glucose uptake and metabolism are impaired in AD brain,
and this impairment appears to be a cause, rather than a con-
sequence, of neurodegeneration [7]. We recently demonstratedAbbreviations: AD, Alzheimer disease; GFAP, glial ﬁbrillary acidic
protein; GlcNAc, b-N-acetylglucosamine; GLUTs, glucose transport-
ers; HIF-1, hypoxia-inducible factor 1; NFTs, neuroﬁbrillary tangles
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doi:10.1016/j.febslet.2007.12.035that impaired glucose uptake/metabolism leads to hyper-
phosphorylation of tau via down-regulation of tau O-GlcNA-
cylation [8,9], which is a unique type of O-glycosylation by
which b-N-acetylglucosamine (GlcNAc) attaches to the hydro-
xyl group of serine or threonine residues and serves as a sensor
of intraneuronal glucose metabolism and regulates protein
phosphorylation inversely. These ﬁndings provide a possible
mechanism by which the impaired glucose uptake/metabolism
could contribute to neurodegeneration in AD [5].
The causes of the impairment of glucose uptake/metabolism
in AD brain are not well understood. Because brain neurons
are unable to synthesize or store glucose, they are fully depen-
dent on glucose transport across the blood–brain barrier,
which is facilitated by glucose transporters (GLUTs). To date,
14 GLUTs have been reported in the human tissue [10]. In
mammalian brain, GLUT1 and GLUT3 are the predominant
GLUTs responsible for glucose transport [11]. GLUT1 is
highly expressed in the endothelial cells of blood–brain barrier
and is responsible for transporting glucose from blood into the
extracellular space of the brain [12,13]. GLUT3 is the major
neuronal GLUT and helps transport glucose from the extracel-
lular space into the neurons [14]. In addition, GLUT2 is ex-
pressed in astrocytes of the brain. GLUT4, which is
expressed mainly in peripheral tissue such as muscle, adipose
tissue and heart, is also found in some neurons in the brain
[14] and, unlike GLUT1-3, is insulin-sensitive. Decreased
GLUT1 and GLUT3 have been observed in AD brain [15–
17], suggesting that this decrease might contribute to the
impairment of brain glucose uptake/metabolism. However,
no evidence of such a possibility has been reported.
In this study, we compared the four major brain GLUTs,
GLUT1-4, between 7 AD and 7 control brains and found that
the decrease in GLUT1 and GLUT3 levels correlates to the de-
crease in O-GlcNAcylation and to the hyperphosphorylation
of tau. We also found that the decrease in GLUT1 and
GLUT3 might result from down-regulation of the transcrip-
tion factor hypoxia-inducible factor 1 (HIF-1) in AD brain.
These ﬁndings reveal a possible mechanism by which GLUT
deﬁciency leads to neurodegeneration in AD.2. Materials and methods
2.1. Human brain tissue
Frozen human brain tissue was obtained from the Sun Health Re-
search Institute Donation Program (Sun City, AZ). The use of the tis-
sue was in accordance with the National Institutes of Health guidelinesblished by Elsevier B.V. All rights reserved.
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The frontal cortices of seven control (86.6 ± 2.9 years old, two males
and ﬁve females, 3.0 ± 0.3 h postmortem delays, Braak stages II–III)
and 7 AD (86.3 ± 6.0 years old, one male and six females, 2.5 ± 0.6 h
postmortem delays, Braak stages V–VI) subjects were used in this
study. All brain samples were conﬁrmed pathologically and stored at
70 C until use.2.2. Antibodies
The primary antibodies used in this study include polyclonal anti-
GLUT1, anti-GLUT3 and anti-HIF-1a from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA); polyclonal anti-GLUT2 and anti-calbindin
from Chemicon (Temecula, CA); polyclonal anti-GLUT4 and mono-
clonal anti-HIF-1b from Abcam (Cambridge, MA); monoclonal
anti-actin from Sigma–Aldrich (St. Louis, MO); monoclonal antibody
(RL2) against O-GlcNAcylated proteins from Aﬃnity Bioreagents
(Golden, CO); phosphorylation-dependent and site-speciﬁc tau anti-
bodies from BioSource International (Camarillo, CA); and monoclo-
nal anti-GFAP from Sternberger Monoclonals (Lutherville, MD).
The secondary antibodies were peroxidase-conjugated goat anti-rabbit
or goat anti-mouse IgG from Jackson ImmunoResearch Laboratories
(West Grove, PA).Fig. 1. Levels of GLUT1–4 in AD and control brains. (A) Crude
extracts of the frontal cerebral cortices from 7 AD and 7 control cases
were analyzed by Western blots developed with antibodies to GLUT1,
GLUT2, GLUT3 or GLUT4. Actin blot was included as a loading2.3. Western blots and immuno-dot-blots
The frozen frontal cortices were homogenized in cold buﬀer contain-
ing 50 mM Tris–HCl (pH 7.4), 2.0 mM EDTA, 10 mM b-mercap-
toethanol and 8.5% sucrose. The homogenates were centrifuged at
15000 · g for 10 min, and the resulting supernatants (crude extracts)
were used for Western blot analyses after protein assay by modiﬁed
Lowry methods [18]. Western blots were carried out by using 10%
SDS-PAGE and standard procedure and developed by using enhanced
chemiluminescence kit (Pierce Biotechnology, Rockford, IL). Levels of
O-GlcNAcylation and tau phosphorylation at individual phosphoryla-
tion sites were determined by immuno-dot-blot assay of the brain ex-
tracts, as described previously [19].control. (B) The blots were quantiﬁed densitometrically and normal-
ized by the actin blot. Data are presented as percentage of controls
(means ± S.D.; *, P < 0.05).2.4. Correlation and statistic analysis
Linear correlations between GLUT levels and levels of O-GlcNAcy-
lation or tau phosphorylation or tangle density in human brains were
analyzed by using MS Excel. Comparisons of means between groups
were analyzed by Students t-test.3. Results
3.1. Levels of various GLUTs are diﬀerentially altered in AD
brain
We ﬁrst determined the levels of four major brain GLUTs
(GLUT1–4) in 7 AD and 7 age-matched control brains by
quantitative Western blots. We found that the levels of
GLUT1 and GLUT3 were signiﬁcantly decreased (25–30%)
in AD brain as compared with controls (Fig. 1), whereas there
was no signiﬁcant diﬀerence in GLUT4 level between the two
groups. In contrast and surprisingly, the GLUT2 level was
found to be markedly increased (1.5-fold) in AD brain.
Fig. 2. Correlation between levels of protein O-GlcNAcylation and
GLUT1. Levels of protein O-GlcNAcylation and GLUT1 in the crude
extracts of the frontal cortices from 7 AD and 7 control cases were
determined by immuno-dot-blots developed with monoclonal antibody
RL2 and quantitative Western blots developed with anti-GLUT1,
respectively. The levels of O-GlcNAcylation (RL2) were then plotted
against the levels of GLUT1. A linear regression line is shown in the
graph.3.2. Decrease in GLUT1 and GLUT3 levels correlates to
decrease in protein O-GlcNAcylation level
To study whether decrease in GLUT1 and GLUT3 levels
contributes to decreased intracellular glucose metabolism
and, thus, decreased protein O-GlcNAcylation, we determined
protein O-GlcNAcylation levels in the crude brain extracts of
AD and control cases. Linear correlation analysis between
O-GlcNAcylation level and levels of GLUT1 or GLUT3 indi-
cated that the O-GlcNAcylation level correlated positively to
both GLUT1 level (Fig. 2, r = 0.60, P < 0.05) and GLUT 3
level (r = 0.52, P < 0.05) in human brain. These observationssupport the contribution of the decrease in GLUT1 and
GLUT3 to decreased glucose uptake/metabolism and O-Glc-
NAcylation in AD brain.
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increase in tau phosphorylation and in numbers of NFTs
O-GlcNAcylation and phosphorylation of tau regulate each
other reciprocally [8,9], and impaired brain glucose uptake/
metabolism is thought to contribute to neurodegeneration.
Therefore, we investigated whether the decrease in GLUT1
and GLUT3 levels contributes to hyperphosphorylation of
tau, which is crucial to neuroﬁbrillary degeneration [5,6]. To-
wards this goal, we measured tau phosphorylation levels at
multiple individual phosphorylation sites that are abnormally
hyperphosphorylated in AD brain, and then carried out corre-
lation analysis between tau phosphorylation and the GLUT1
and GLUT3 levels in AD and control brains. We found that
the GLUT1 level strongly correlated negatively to the level
of tau phosphorylation at the phosphorylation sites studied
(Fig. 3). The negative correlations were statistically signiﬁcant
at all the phosphorylation sites except Ser404. Similar negative
correlations between GLUT3 level and tau phosphorylation
were also observed, but the correlations reached statistical sig-
niﬁcance only for phosphorylation of tau at Ser214 and Ser262
(Table 1). In addition, we also analyzed correlations between
the GLUT1 and GLUT3 levels and the densities of NFTs in
the frontal cortex, where the levels of GLUT1 and GLUT3
were determined, and in the whole brains. We found that the
GLUT1 and GLUT3 levels were also correlated inversely to
the densities of NFTs (Table 1). These results provide evidence
that the decrease in GLUT1 and GLUT3 may contribute to
abnormal hyperphosphorylation of tau and neuroﬁbrillary
degeneration.
3.4. HIF-1 is decreased in AD brain
We further studied the potential cause of the reduction of
GLUT1 and GLUT3 levels in AD brain. Because the expres-
sion of GLUT1 and GLUT3 in the brain is mainly regulatedFig. 3. Correlation between GLUT1 levels and tau phosphorylation at
phosphorylation in crude extracts of the frontal cortices from 7 AD and 7 con
dot-blots, respectively. The levels of tau phosphorylation at individual pho
regression line is shown when the correlation reached statistical signiﬁcance.by HIF-1 [20–23], a heterodimer transcription factor consisting
of HIF-1a and HIF-1b, we compared the levels of HIF-1a and
HIF-1b between AD and control brains. We found that HIF-
1a level was markedly reduced (to 40% of controls) in AD
brain (Fig. 4). A 20% decrease in HIF-1b was also observed
in AD brain, but the reduction did not reach statistical signif-
icance. These results suggest that the decrease in GLUT1 and
GLUT3 might result from down-regulation of HIF-1 in AD
brain.
GLUT3 is the major neuronal GLUT [14]. To reveal
whether a potential neuronal loss may also underlie the de-
crease in GLUT3 in AD brain, we determined the level of cal-
bindin, a commonly used neuronal marker [24]. We found no
diﬀerence in calbindin level between AD and control brains
(Fig. 5), thus excluding the possibility that the decrease in
GLUT3 we observed in the frontal cortices of AD brain were
the consequence of neuronal loss.
3.5. Increase in GLUT2 level in AD brain might result from
astrocyte activation
In contrast to the decrease in GLUT1 and GLUT3 levels, we
were surprised to observe a dramatic elevation of GLUT2 level
in AD brain (Fig. 1). Because GLUT2 is only expressed in
astrocytes in the mammalian brain [14], we tested whether
the elevation of GLUT2 in AD brain was due to astrocyte acti-
vation. To quantify astrocytes in the brain samples, we deter-
mined the level of glial ﬁbrillary acid protein (GFAP), an
astrocyte marker, by Western blots and found that the GFAP
level in the AD group was 2.2 fold of that in the control
group (Fig. 5). When the GLUT2 level was normalized by
the GFAP level, the elevation of GLUT2 in AD brain disap-
peared (data not shown). These results suggest that the higher
level of GLUT2 we observed in AD might result from astro-
cyte activation.individual phosphorylation sites. Levels of GLUT1 and of tau
trol cases were determined by quantitative Western blots and immuno-
sphorylation sites were then plotted against GLUT1 levels. A linear
Table 1
Correlation between the levels of GLUT1 or GLUT3 and the levels of tau phosphorylation at individual phosphorylation sites and the density of
NFTs
Phosphorylation sites of tau NFTs density
S199 S202 T205 T212 S214 S217 S262 S396 S404 S422 Frontal Total
GLUT1 r value 0.616 0.692 0.673 0.627 0.657 0.640 0.588 0.662 0.500 0.623 0.67 0.61
P value 0.018 0.006 0.008 0.016 0.010 0.013 0.026 0.009 0.068 0.017 0.008 0.022
GLUT3 r value 0.412 0.510 0.495 0.520 0.583 0.483 0.597 0.453 0.359 0.471 0.54 0.45
P value 0.142 0.062 0.071 0.056 0.028 0.079 0.024 0.103 0.206 0.089 0.045 0.109
The GLUT levels and the levels of tau phosphorylation at individual phosphorylation sites in the frontal cortices were determined by quantitative
Western blots and immuno-dot-blots, respectively. The density of NFTs was scored by 0 (none), 1 (sparse), 2 (moderate) and 3 (frequent) in each of
the ﬁve areas (frontal, temporal, parietal, hippocampal and entorhinal), as deﬁned according to CERAD AD criteria [30]. The total tangle density
was calculated by adding up the scores from all the ﬁve areas. The P values that reach statistic signiﬁcance (P < 0.05) are highlighted.
Fig. 4. Levels of HIF-1a and HIF-1b in AD and control brains. (A)
Homogenates of frontal cerebral cortices from 7 AD and 7 control
cases were analyzed by Western blots developed by anti-HIF-1a or
anti-HIF-1b. Actin blot was included as a loading control. (B) The
blots were quantiﬁed densitometrically and normalized by the actin
blot. Data are presented as percentage of the controls (means ± S.D.;
#, P < 0.05).
Fig. 5. Levels of calbindin and GFAP in AD and control brains. (A)
Crude extracts of frontal cerebral cortices from 7 AD and 7 control
cases were analyzed by Western blots developed with anti-calbindin or
anti-GFAP. Actin blot was included as a loading control. (B) The blots
were quantiﬁed densitometrically and normalized by the actin blot.
Data are presented as percentage of the controls (means ± S.D.; *,
P < 0.05).
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Glucose is the primary source of the energy required for
brain activity, although it cannot enter the brain freely. The
transport of glucose from the bloodstream into the brain is
mediated by GLUTs. In this study, we used a cohort of autop-
sied brains with short postmortem (<3 h average postmortem
delay) and matched ages and compared the levels of four ma-
jor brain GLUTs between AD and controls. We found that
GLUT1 and GLUT3 were signiﬁcantly decreased in AD brain.
These ﬁndings are consistent with a previous observation made
by using diﬀerent brain samples, in which the ages (76 ± 5
years in AD vs. 56 ± 22 years in controls) and postmortem de-
lays (8.7 ± 4 h in AD vs. 12.5 ± 6 h in controls) between thetwo groups were not matched [16]. Although it is generally as-
sumed that glucose transport across blood–brain barrier and
uptake into neurons and glial cells is not the rate-limiting step
in glucose utilization in normal brains, under pathological con-
ditions such as AD, the decreased GLUT1 and GLUT3 levels
may impair the glucose-transporting ability to a threshold that
leads to impaired glucose uptake/metabolism. Our ﬁndings
that the levels of GLUT1 and GLUT3 correlate positively to
O-GlcNAcylation and negatively to tau phosphorylation and
the density of NFTs in human brain strongly support this pos-
sibility.
To investigate whether the reduction of GLUT3 in AD brain
is caused by a possible neuronal loss that had been reported
previously, we examined neuronal loss of the same tissue sam-
ples (frontal cortex) as used for GLUT3 study by measuring
the level of calbindin, a commonly used neuronal marker.
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which is consistent with the recent studies showing signiﬁcant
neuronal loss mainly in the hippocampus and entorhinal cor-
tex of AD brain [25]. These results suggest that the decrease
in neuronal GLUT3 is most likely speciﬁc to AD rather than
being simply caused by neuronal loss. The speciﬁcity of
GLUT3 reduction is also supported by the observation of no
signiﬁcant diﬀerence in GLUT4 between AD and controls.
Expression of GLUT1 and GLUT3 is mainly regulated by
HIF-1 [20–23]. HIF-1 has two subunits, HIF-1a and HIF-1b
[26]. The latter is constitutively expressed in the nucleus, and
the transcription activity is mainly regulated by HIF-1a, which
translocates from cytosol into the nucleus and forms a hetero-
dimer with HIF-1b to activate the related gene expression [27].
Our ﬁnding that HIF-1, especially HIF-1a, was decreased in
AD brain suggests that this decrease might be a cause of the
reduction of GLUT1 and GLUT3. We currently do not know
how HIF-1 is down-regulated in AD brain. Because oxidative
stress, which is increased in AD brain [28], can destabilize
HIF-1 [29], it is possible that the decreased HIF-1 in AD brain
is due to increased oxidative stress.
In contrast to GLUT1 and GLUT3 levels, we observed that
GLUT2 level was more than two times higher in AD brain
than in control. To understand this surprising observation,
we determined the degree of astrocyte activation in AD brain.
We found that the astrocytes are activated to a similar extent
as the GLUT2 elevation in AD. Because GLUT2 is only
expressed in astrocytes in the brain [14], it is likely that the
elevated GLUT2 level we observed results from astrocyte
activation in AD.
The most important and novel ﬁndings of this study are the
positive correlation between protein O-GlcNAcylation and
levels of GLUT1 and GLUT3 as well as the negative correla-
tion between tau phosphorylation/tangle density and levels of
GLUT1 and GLUT3. These ﬁndings provide, for the ﬁrst
time, a linkage between deﬁcient brain GLUTs and tau pathol-
ogy in AD brain. These ﬁndings are consistent with the
hypothesis that impaired brain glucose uptake/metabolism
contributes to AD neuroﬁbrillary degeneration via down-regu-
lation of O-GlcNAcylation and upregulation of tau phosphor-
ylation [5].
In conclusion, we studied the levels of major GLUTs, pro-
tein O-GlcNAcylation and tau phosphorylation in AD brain
as compared with controls. We found that GLUT1 and
GLUT3 levels were signiﬁcantly decreased, whereas GLUT2
was dramatically increased in AD brain. The decrease in
GLUT1 and GLUT3 levels may result from down-regulation
of HIF-1, which was also observed in AD brain. On the other
hand, elevation of GLUT2 appears to be caused by the astro-
cyte activation seen in AD brain. More importantly, we found
that the decrease in GLUT1 and GLUT3 levels correlated to
the decrease in O-GlcNAcylation and to the hyperphosphory-
lation of tau at multiple abnormal phosphorylation sites seen
in AD brain. These studies provide important evidence that
deﬁciency of GLUTs contributes to abnormal hyperphosph-
orylation of tau and Alzheimer neuroﬁbrillary degeneration.
Improving brain glucose transport could be a potential thera-
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